Evidence map›Paper›PMID 33030980›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.

Andrew M Evens, Susan K Parsons

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Andrew M EvensRutgers Cancer Institute of New Jersey, New Brunswick, NJ.ORCID 0000-0002-6900-1824
Susan K ParsonsDepartments of Pediatrics and Medicine, Tufts University School of Medicine; and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.ORCID 0000-0003-0282-6490

Funding

Artificial, Humanized Stem Cell NichesR01EB012521 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI PAREKKADAN, BIJU · 2011 to 2021
$6.0M
Computing, Optimizing, and Evaluating Quantitative Cancer Imaging BiomarkersU01CA187947 · NCI · STANFORD UNIVERSITY · PI NAPEL, SANDY A., RUBIN, DANIEL L · 2015 to 2019
$2.9M
Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platformR33CA223908 · NCI · NORTHEASTERN UNIVERSITY · PI EVENS, ANDREW M, HUANG, TONY JUN · 2018 to 2020
$1.2M
An integrated acoustofluidic droplet-sorting platform for classification of lymphocyte activity and functional phenotyping at single cell levelR01GM127714 · NIGMS · NORTHEASTERN UNIVERSITY · PI KONRY, TANIA TALI · 2018 to 2021
$1.2M
NCI NIH HHS R33 CA223908NCI NIH HHS U01 CA187947NIBIB NIH HHS R01 EB012521NIGMS NIH HHS R01 GM127714
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hodgkin DiseaseLymphoma, Non-HodgkinCause of DeathContinuity of Patient CareHumansMorbidity

Identifiers

PMID33030980
PMCPMC7723688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.